Aethlon Medical Inc (AEMD) Exchange: NASDAQ

Aethlon Medical, Inc. is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections. In preclinical studies in cancer, the Hemopurifier depletes the presence of circulating tumor-derived exosomes that are believed to promote immune suppression. These tumor derived exosomes also appear to seed the spread of metastases and therefore may inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The FDA has approved an Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Hemopurifier ® in patients with head and neck cancer in combination with standard of care pembrolizumab (Keytruda). The Hemopurifier also is an FDA designated "Breakthrough Device" related to life-threatening viruses that are not addressed with approved therapies. The FDA also has approved a supplement to the Company's existing IDE to allow for the testing of the Hemopurifier ® in patients with SARS-CoV-2/COVID-19 in a new feasibility study. Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.